Regulation of matrix metalloproteinase expression

Drug Discovery Today: Disease Models

Volumn 8, Issue 1, 2011, Pages 5-11

  Gorman, Jennifer L ^a   Ispanovic, Eric ^a   Haas, Tara L ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; CHEMICALLY MODIFIED TETRACYCLINE DERIVATIVE; DOXYCYCLINE HYCLATE; DX 2400; GELATINASE A; GELATINASE B; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; NONPEPTIDOMIMETIC AGENT; PEPTIDOMIMETIC AGENT; TANOMASTAT; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL MIGRATION; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; METASTASIS; METASTASIS INHIBITION; NITROSYLATION; NONHUMAN; OXIDATION; REPERFUSION INJURY; TRANSCRIPTION REGULATION;

EID: 82455167842     PISSN: None     EISSN: 17406757     Source Type: Journal    
DOI: 10.1016/j.ddmod.2011.06.001     Document Type: Review

References (71)

1. Woessner, J. F., Jr (1994) The family of matrix metalloproteinases. Ann. N. Y. Acad. Sci. 732, 11-21
2. Birkedal-Hansen, H. et al. (1993) Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 4, 197-250 (Pubitemid 23103292)
3. Huovila, A. P. et al. (2005) Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 30, 413-422
4. Salter, R. C. et al. (2010) ADAMTS proteases: key roles in atherosclerosis? J. Mol. Med. 88, 1203-1211
5. Yan, C. and Boyd, D. D. (2007) Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 211, 19-26 (Pubitemid 46363892)
6. Alfonso-Jaume, M. A. et al. (2006) Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am. J. Physiol. Heart Circ. Physiol. 291, H1838-H1846 (Pubitemid 44497691)
7. Spinale, F. G. (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 87, 1285-1342 (Pubitemid 350041472)
8. Clark, I. M. et al. (2008) The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 40, 1362-1378
9. Boyd, P. J. et al. (2005) MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am. J. Physiol. Cell Physiol. 288, C659-C668 (Pubitemid 40229495)
10. Haas, T. L. (2005) Endothelial cell regulation of matrix metalloproteinases. Can. J. Physiol. Pharmacol. 83, 1-7 (Pubitemid 40754769)
11. Liu, X. et al. (2010) Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochem. Biophys. Res. Commun. 396, 219-223
12. Han, X. et al. (2003) Transcriptional up-regulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2. J. Biol. Chem. 278, 47785-47791 (Pubitemid 37523225)
13. Doyle, J. L. and Haas, T. L. (2009) Differential role of beta-catenin in VEGF and histamine-induced MMP-2 production in microvascular endothelial cells. J. Cell Biochem. 107, 272-283
14. Takahashi, M. et al. (2002) Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 21, 5861-5867 (Pubitemid 35007236)
15. Knapinska, A. M. et al. (2005) Molecular mechanisms regulating mRNA stability: physiological and pathological significance. Curr. Genomics 6, 471-486 (Pubitemid 41671666)
16. Kandasamy, A. D. et al. (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc. Res. 85, 413-423
17. Steele, R. et al. (2010) MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 1, 381-387
18. Roy, S. et al. (2009) MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 82, 21-29
19. Ra, H. J. and Parks, W. C. (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596 (Pubitemid 350180394)
20. Nagase, H. (1997) Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378, 151-160 (Pubitemid 27230597)
21. Murphy, G. et al. (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS 107, 38-44 (Pubitemid 29133521)
22. Strongin, A. Y. et al. (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. J. Biol. Chem. 270, 5331-5338
23. Brooks, P. C. et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alphav beta3. Cell 85, 683-693 (Pubitemid 26181048)
24. Tchougounova, E. et al. (2005) A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J. Biol. Chem. 280, 9291-9296 (Pubitemid 40409621)
25. Sariahmetoglu, M. et al. (2007) Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J. 21, 2486-2495 (Pubitemid 47230678)
26. Baker, A. H. et al. (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719-3727 (Pubitemid 35203598)
27. Noda, M. et al. (2003) RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev. 22, 167-175 (Pubitemid 36561056)
28. Haas, T. L. et al. (2000) Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 279, H1540-H1547
29. Rivilis, I. et al. (2002) Differential involvement of MMP-2 and VEGF during muscle stretch-versus shear stress-induced angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 283, H1430-H1438
30. Rullman, E. et al. (2007) A single bout of exercise activates matrix metalloproteinase in human skeletal muscle. J. Appl. Physiol. 102, 2346-2351 (Pubitemid 47080770)
31. Rullman, E. et al. (2009) Endurance exercise activates matrix metalloproteinases in human skeletal muscle. J. Appl. Physiol. 106, 804-812
32. Chintala, S. K. et al. (1996) Role of extracellular matrix proteins in regulation of human glioma cell invasion in vitro. Clin. Exp. Metastasis 14, 358-366 (Pubitemid 26363210)
33. Haas, T. L. et al. (1998) Three dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP- 2 in microvascular endothelial cells. J. Biol. Chem. 273, 3604-3610 (Pubitemid 28109785)
34. Chan, V. T. et al. (1998) Membrane type matrix metalloproteinases in human dermal microvascular endothelial cells: expression and morphogenetic correlation. J. Invest. Derm. 111, 1153-1159 (Pubitemid 29115190)
35. Milkiewicz, M. et al. (2007) Static strain stimulates expression of matrix metalloproteinase-2 and VEGF in microvascular endothelium via JNK-and ERK-dependent pathways. J. Cell Biochem. 100, 750-761 (Pubitemid 46180536)
36. Ispanovic, E. and Haas, T. L. (2006) JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells. Am. J. Physiol. Cell Physiol. 291, C579-C588 (Pubitemid 44497584)
37. Ispanovic, E. et al. (2008) Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation. Am. J. Physiol. Cell Physiol. 295, C600-C610
38. Nateri, A. S. et al. (2005) Interaction of phosphorylated c-Jun. with TCF4 regulates intestinal cancer development. Nature 437, 281-285 (Pubitemid 41294493)
39. Ha, C. H. et al. (2008) VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 28, 1782-1788
40. Xu, J. et al. (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154, 1069-1079 (Pubitemid 34286185)
41. Bergers, G. et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744
42. Onimaru, M. et al. (2010) An autocrine linkage between matrix metalloproteinase-14 and Tie-2 via ectodomain shedding modulates angiopoietin-1-dependent function in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 30, 818-826
43. Dean, R. A. et al. (2007) Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell Biol. 27, 8454-8465
44. Haas, T. L. et al. (2007) Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am. J. Physiol. Heart Circ. Physiol. 293, H2429-H2437 (Pubitemid 47605890)
45. Ruddy, J. M. et al. (2010) Differential effect of wall tension on matrix metalloproteinase promoter activation in the thoracic aorta. J. Surg. Res. 160, 333-339
46. Raffetto, J. D. and Khalil, R. A. (2008) Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 6, 158-172
47. Yun, S. et al. (2002) Transcription Factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloprotinase expression in endothelium. J. Biol. Chem. 277, 34808-34814
48. Milkiewicz, M. et al. (2008) Shear stress-induced Ets-1 modulates protease inhibitor expression in microvascular endothelial cells. J. Cell Physiol. 217, 502-510
49. Newby, A. C. (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 28, 2108-2114
50. Lemarie, C. A. et al. (2010) Extracellular matrix alterations in hypertensive vascular remodeling. J. Mol. Cell Cardiol. 48, 433-439
51. Kuzuya, M. et al. (2003) Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 108, 1375-1381 (Pubitemid 37174417)
52. Kuzuya, M. et al. (2006) Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26, 1120-1125 (Pubitemid 43732121)
53. Galis, Z. S. et al. (2002) Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 91, 852-859 (Pubitemid 35285084)
54. Chen, K. C. et al. (2011) OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J.
55. Castro, M. M. et al. (2011) Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol. Res.
56. Shiraya, S. et al. (2006) Hypertension accelerated experimental abdominal aortic aneurysm through upregulation of nuclear factor kappaB and Ets. Hypertension 48, 628-636 (Pubitemid 44843866)
57. Castro, M. M. et al. (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198, 320-331 (Pubitemid 351707391)
58. Rodrigues, S. F. et al. (2010) Matrix metalloproteinases cleave the beta2- adrenergic receptor in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 299, H25-H35
59. Tran, E. D. et al. (2010) Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J. Vasc. Res. 47, 423-431
60. Raffetto, J. D. and Khalil, R. A. (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 75, 346-359 (Pubitemid 350298459)
61. Myers, J. E. et al. (2005) MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens. Pregnancy 24, 103-115 (Pubitemid 40911348)
62. Matsusaka, H. et al. (2006) Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47, 711-717 (Pubitemid 43740243)
63. Spinale, F. G. et al. (2010) Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J. Biol. Chem. 285, 30316-30327
64. Lee, J. G. et al. (2005) Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc. Natl. Acad. Sci. U. S. A. 102, 16345-16350 (Pubitemid 41688916)
65. Lindsey, M. L. et al. (2006) Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 290, H232-H239
66. Ducharme, A. et al. (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106, 55-62 (Pubitemid 30437240)
67. Konstantinopoulos, P. A. et al. (2008) Matrix metalloproteinase inhibitors as anticancer agents. Int. J. Biochem. Cell Biol. 40, 1156-1168
68. Gialeli, C. et al. (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278, 16-27
69. Devy, L. et al. (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517-1526
70. Sela-Passwell, N. et al. (2010) Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition? Biochim. Biophys. Acta 1803, 29-38
71. Williams, J. M. et al. (2011) Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 300, F983-F998